BioSpace News Archive

Neogen announced today that its revenues for the second quarter of its 2018 fiscal year, which ended Nov. 30, increased 12% to $101,817,000, from the previous year’s second quarter revenues of $90,717,000.

resTORbio announced that Lynne Sullivan, Senior Vice President of Finance for Biogen, Inc. has joined the resTORbio board of directors as an independent director.

Axonics expects to implant approximately 120 patients at 15 centers of excellence located in the U.S. and Western Europe.

The newly formed board will be chaired by the former CEO of the ASCO, Dr. Allen Lichter, who is joined by Dr. Shaomeng Wang, Ascentage’s Co-founder and CSO, and the Warner-Lambert/Parke-Davis Professor in Medicine at the University of Michigan, among other internationally recognized clinical oncology researchers and specialists.

H2-Pharma announced today that it has re-launched XENICAL (orlistat) 120 mg Capsules via its newly formed Branded division.

The technology will enable new products for a leading segment of RB’s product portfolio. Detailed financial terms were not disclosed.

China Biologic Products today announced that it has completed the acquisition of 80% equity interest in Tianxinfu from PW Medtech Group Limited.

The new 7600 square feet custom-built, state-of-the-art facility hosts Denovo’s biomarker discovery platform, US clinical team and serves as Denovo’s US headquarters.

Under the terms of the license agreement, United Therapeutics has been granted an exclusive license to Corsair’s intellectual property for the development of treprostinil prodrug formulations.

Maravai, a leader in providing specialty reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide, today announced the acquisition of Sterling, VA based Glen Research.